Elranatamab (Elrexfio, Pfizer) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 antibody and have demonstrated disease progression on the last therapy'.
The dosage schedule is available in the summary of product characteristics for elranatamab.
The list price for elranatamab is £4,242.50 per 76‑mg vial and £2,456.00 per 44‑mg vial, (excluding VAT; BNF, accessed October 2024).
The company has a commercial arrangement. This makes elranatamab available to the NHS with a discount. The size of the discount is commercial in confidence.